ClinicalTrials.gg
RecruitingNCT07359664Updated Jan 22, 2026

OCTA in Cardiovascular Disease and Healthy Controls

An interventional study of Retinal vascular assessment using OCTA and SLDF in Patients With Cardiovascular Disease and Healthy Participants, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School — 2 open to participants now, 3 under way, none of them phase 3. Hypertension · University of Erlangen-Nürnberg Medical School.

Planned enrollment
4th of 11
64 · median 28
Started
2025
the only one that year
No phase
6 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 6 with no phase, and was the 13th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, or all of them as a file.
02

Study summary

This prospective clinical study will involve the non-invasive assessment of retinal vessels using OCTA (Cirrus OCT 6000 AngioPlex) and scanning laser Doppler flowmetry (SLDF) in patients with cardiovascular disease and healthy individuals. The study will be conducted at the Clinical Research Centre (CRC), Department of Nephrology and Hypertension at the University of Erlangen-Nuremberg.

Read the detailed description

Each patient (32 patients) and healthy individual (32 healthy individuals) undergoes one study visit. After providing informed consent, each patient and healthy individual receives an assessment of their retinal vessels using OCTA and SLDF. In the sub-study of 10 patients with cardiovascular disease, the reliability of the OCTA measurements will be determined. Each patient will receive three study visits (with an OCTA and SLDF assessment on each occasion) on three different days.

03

Conditions studied

  • Patients With Cardiovascular Disease
  • Healthy Participants

Keywords

  • arterial hypertension
  • type 2 diabetes mellitus
  • chronic kidney disease
  • heart failure
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria for patients with cardiovascular disease:

  • cardiovascular disease defined as one or more of the following: arterial hypertension, type 2 diabetes mellitus, chronic kidney disease, heart failure

Inclusion criteria

Inclusion Criteria for healthy individuals:

  • 18-29.9 kg/m2
  • Non-smoker
  • Good general health, as determined by study personnel based on assessments of previous visits, including anamnesis, vital signs, physical examination and clinical laboratory parameters.

Exclusion criteria for patients with cardiovascular disease:

  • Active ophthalmological (retinal) disease resulting in impaired visual assessment of retinal vessels (e.g. glaucoma, cataracts, retinal oedema).

Exclusion criteria

Exclusion criteria for healthy individuals:

  • Active ophthalmological (retinal) disease with reduced visual assessment of retinal vessels (e.g. glaucoma, cataracts, retinal oedema).
  • deviation in physical examination, vital signs, or laboratory parameters (based on the physician's clinical judgement).
  • a clinically relevant history of cardiovascular disease or any other previously known cardiovascular disease
  • History of clinically relevant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine or other diseases
  • office blood pressure above or equal to 140/90 mmHg
  • Office heart rate outside of the following range: 50-99 bpm
  • regular intake of any medication for the treatment of cardiovascular diseases (e.g. antihypertensive or antidiabetic medication) within one month before study inclusion
  • alcohol or drug abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Other
    Assessment of retinal vessels

    OCTA and SLDF based assessment of retinal vasculature

    Diagnostic Test: Retinal vascular assessment using OCTA and SLDF

Interventions

  • Diagnostic testRetinal vascular assessment using OCTA and SLDF

    Assessment of retinal capillary density using OCTA and SLDF

06

What researchers measure

Primary outcomes

  1. Assessment of reliability of OCTA based assessment of retinal capillary density in patients with CV disease

    Assessment of test-retest-reliability between 3 study visits for OCTA based assessment of retinal capillary density in patients with CV disease

    Time frame: test-retest-reliability between 3 study visits (between each visit needs to be a time gap of at least 24 hours, all visits will be performed within two weeks)

Secondary outcomes

  1. comparison of OCTA based retinal capillary density between CV diseased patients and healthy controls

    comparison of OCTA based retinal capillary density between CV diseased patients and healthy controls

    Time frame: one study visit in each group, baseline values at day 1 are compared

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 22, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359664
Collaborators
German Diabetes Association
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Dec 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 22, 2026

Study contacts

Agnes Bosch, MD
Contact
agnes.bosch@uk-erlangen.de
+49 9131 8536245
Dennis Kannenkeril, MD
Contact
CRC.M4@uk-erlangen.de
+49 911 80099760
Agnes Bosch, MD
principal investigator · Clinical Research Center, Department of Nephrology and Hypertension, Universityhospital Erlangen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion